• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Data
 

Data

on

  • 257 views

 

Statistics

Views

Total Views
257
Views on SlideShare
246
Embed Views
11

Actions

Likes
0
Downloads
0
Comments
0

1 Embed 11

http://lca.epilepsy.org.uk 11

Accessibility

Categories

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment
  • EXAMPLES

Data Data Presentation Transcript

  • Working in partnership to deliver better Epilepsy services 31/01/13 ManchesterMatt Eddleston and Kate Trenam - Healthcare Partnership Managers
  • Agenda A brief look at UCB Objective of this session The HPM Role and 2013 Objectives Data tools for commissioning services Data examples and case study Working together – How and Who’s who? Next steps
  • UCB: A patient-centric biopharma leader Focusing on severe diseases in Immunology and the Central Nervous System 2011 revenue: €3.2 billion More than 8,000 employees globally Operations in more than 40 countries R&D Spend: 24% of revenue Listed on Euronext Stephanie, living with rheumatoid arthritis 3 Mar 2012: UK/12MIS0027
  • UCB - Our Global Presence 4 Mar 2012: UK/12MIS0027
  • UCB’s vision and strategies 5 Mar 2012: UK/12MIS0027
  • UCB in the UK 6 Carrie, living with Crohn’s disease Mar 2012: UK/12MIS0027
  • UCB in the UK Our UK site houses the immunology research hub and the head office for the UK commercial organisation UK research hub focuses on research for conditions such as rheumatoid arthritis, epilepsy, lupus and osteoporosis Employing approx 600 staff in the UK; 400 in R&D Recently invested £25 million in the ‘UCB Biologics R&D Centre’; state-of-the-art laboratory 7 Mar 2012: UK/12MIS0027
  • UCB in the UK A top 5 investor in UK Pharmaceutical Research & Development (R&D): investing >£230 million in 2010* Providing over 50 approved medicines within the UK Supporting ~30 UK PhDs at any one time Spending more than €500,000 annually on PhD support * Based upon data in the 2010 BIS R&D Scoreboard (BIS = Department for Business, 8 Innovation & Skills Mar 2012: UK/12MIS0027
  • Summary Against a backdrop of dramatic job cuts & reductions spend from many pharma companies; UCB has a more positive story to tell We want to stay at the cutting edge; as a result we invest heavily in R&D • In 2011, R&D accounted for 24% of revenue • 40% of our research spend is in the UK and we continue to invest in new facilities and research Industry and academic and voluntary sector partnerships are essential for UCB 9 Mar 2012: UK/12MIS0027
  • Objective Provide clear understanding of HPM role Provide a clear understanding of the data tools and how we use them Provide a clear understanding of Commissioning Advocate Objectives Identify opportunities for working together Agree next steps
  • UCB Healthcare Partnership Managers The NHS is changing The industry model is changing Focus on the whole health economy not just on the benefits of the drugs we produce • Government • National Commissioning • Local Commissioning HPM • Trust Managers • Pharmacy • Clinicians
  • Creating Value in the NHS Reducing Costs VALUE Increasing Improving Patient Efficiency Experience
  • HPM objectives 2013 Work in Partnership with the NHS to create value in Epilepsy What is UCB’s offering? Facilitate stakeholder meetings Provide benchmarking data Share best practice Help define the problems and solutions Assist in commissioning through clear business plans Implement and promote the new services
  • The Commissioning CycleNEEDS ANALYSISNEEDS ANALYSIS SERVICE DEVELOPMENT APPROVAL IMPLEMENATIONJSNANational Priorities What are we Launch and PRTrust Priorities changing?QIPPCQUINPatient Pathway NHS Data Best practice Launch meetings Facilitation PR Documentation Impact review Business Case Development Data Modelling
  • Data tools Hospital Episodes Statistics Pathway Simulation Tool NHS data NHS data ICD 10 Codes applied to all QOF or HES procedures Assesses the impact of NHS find it difficult to community services manipulate Simulat8 Quantis database South Yorkshire Epilepsy NE Lincs Neurology Project Project
  • South Yorkshire Epilepsy Project - Context• Epilepsy services are not equitable across the region• Sheffield does not have the capacity to continue with the same number of referrals to their tertiary clinics• This in turn applies pressure on their general neurology clinics• Doncaster and Rotherham per population do not have equitable services to those in Sheffield and BarnsleySTAKEHOLDERS Clinical lead engaged and motivated CCG Commissioner engaged and motivated GP’s engaged
  • Project Objective Deliver equitable and sustainable Epilepsy services in Sheffield, Barnsley, Doncaster and Rotherham • Improve services in Doncaster and Rotherham to relieve pressure on Sheffield
  • Return for the patient and the NHS NHS Patient Reduction in referral costs – Reduction in variation tertiary and general neurology Right treatment right time Reinvestment into community Care closer to home services Better all round management Reduction in variation = better QOL Good model of partnership working in new NHS Return for UCB? HES data
  • Epilepsy pathway simulation tool The Pathway tool ‘Simul8’ uses either HES or QOF data to map the patient pathway from diagnosis through to secondary care It then looks at the impact of introducing community services in the form of specialist nurses and dedicated telephone services The results form the basis of a written report that we will pull together looking at, amongst other things, patient through put and of course cost The next slide is a screen shot of the tool
  • Epilepsy pathway simulation tool
  • Epilepsy pathway simulation tool Typical report
  • Epilepsy Action and UCB working in partnership todeliver better services - Opportunities An alliance to reduce inequalities in epilepsy healthcare The NHS are looking for complete solutions HPM team and Commissioning Advocates: • Same objectives • Compliment each others work • Data provision and funding • Best practice and expertise • Driving Epilepsy on the agenda • Referrals • Local meetings
  • Who’s Who? Harrogate 1) Manchester 2) Stockport Chester le Street Scarborough Sheffield WestMidlands Coventry Dorking London
  • Contact Details matt.eddleston@ucb.com - 07770 960 168 • Lancashire, Merseyside, Greater Manchester, Yorkshire, Lincolnshire Kate.trenham@ucb.com - 07976 600 594 • Sussex, Surrey, Hampshire, IOW, Gloucestershire, Somerset, Devon, C ornwall, Dorset vincenzo.straccia@ucb.com - 07841 959 039 • Norfolk, Suffolk, Greater London, Essex, Kent, Bedfordshire, Cambridgeshire, Northamptonshire suzanne.fletcher@ucb.com - 07713 074 083 • Oxfordshire, Thames Valley, Staffordshire, E&W Midlands, Leicester, Derbyshire, Nottinghamshire david.walter@ucb.com – 07768 107 597 • National Healthcare Partnership Manager • Flip chart Advocate details • ADD GUY A
  • Next Steps HPM to contact equivalent commissioning advocate Agree local meeting Discuss local objectives Agree plan for working together • Are there existing projects where we could work together? • Where could we target together?
  • Questions?